Taro Pharmaceuticals
Taro Pharmaceutical Industries is a research-based generic pharmaceutical manufacturer founded in 1950 that develops, produces, and distributes prescription and OTC medicines across dermatology, cardiology, pediatrics, and neurology for healthcare professionals, pharmacies, and consumers in the US, Canada, Israel, and international markets.
- Company typePrivate
- Founded1950
- HeadquartersHaifa, Israel
- Headcount5,001–10,000
- GTM typeB2B and B2C
- OfferingHardware or Manufacturing
What Taro Pharmaceuticals does
Taro Pharmaceutical Industries is a research-based international pharmaceutical company founded in 1950 in Haifa, Israel, that develops, manufactures, and markets generic prescription (Rx) and over-the-counter (OTC) pharmaceutical products. The company's product portfolio spans dermatology, cardiology, pediatrics, and neurology therapeutic areas, delivered through diverse dosage forms including tablets, capsules, suspensions, solutions, creams, and ointments, including proprietary products such as Pliaglis (lidocaine/tetracaine 7%/7% topical anesthetic) and the TaroPharma branded division established in 2003. Taro operates a vertically integrated manufacturing model with in-house active pharmaceutical ingredient (API) synthesis, with production facilities in Haifa (Israel), Brampton (Canada), and Hawthorne, New York, all FDA-approved and GMP-compliant.
Taro sells through a B2B sales-led go-to-market model, distributing generic Rx and OTC products via pharmacy channels, wholesale distributors, and private-label arrangements with retail chains in the US, Canada, Israel, and international markets. Customer segments include healthcare professionals (physicians, pharmacists), patients and consumers, and retail pharmacies and distributors. Revenue is generated through one-time sales of generic pharmaceutical products and API supply through its Taro API division, with pricing varying by market, dosage, pack size, and contractual terms rather than publicly disclosed schedules. Taro also partners with the non-profit Rx Outreach on a Patient Assistance Program for select critical medications. Since June 24, 2024, Taro has been a privately held, wholly-owned subsidiary of Sun Pharmaceutical Industries following a $454 million merger that ended its NYSE listing.
Taro Pharmaceuticals firmographics
Firmographics- Name
- Taro Pharmaceuticals
- Legal name
- Taro Pharmaceuticals U.S.A., Inc.
- Website
- http://www.taro.com/
- Company type
- Private
- Founded year
- 1950
- Operating status
- Operating
- Headcount range
- 5,001–10,000 employees
- Short description
- Taro Pharmaceutical Industries is a research-based generic pharmaceutical manufacturer founded in 1950 that develops, produces, and distributes prescription and OTC medicines across dermatology, cardiology, pediatrics, and neurology for healthcare professionals, pharmacies, and consumers in the US, Canada, Israel, and international markets.
- Ownership category
- akta.pro rank
Taro Pharmaceuticals industry classification
Industry- Product category
- Generic Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Dermatology & Aesthetics Pharmaceuticals (HLAIAAAK)
- akta.pro secondary industry
- Dermatology Specialty Pharmaceuticals (HLAIACAL)
Keywords
Where Taro Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Haifa
- HQ country
- Israel
- HQ region
- Middle East
Offices3 records
Markets served
Taro Pharmaceuticals business model
Business model- GTM type
- B2B and B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Technology or R&D, Personnel, Marketing or Sales, Infrastructure
Revenue model
- Generic Pharmaceutical Sales: Revenue generated from manufacturing and selling generic prescription (Rx) and over-the-counter (OTC) pharmaceutical products across dermatology, cardiology, pediatrics, and neurology therapeutic areas. Products distributed in US, Canada, Israel and international markets.
- Active Pharmaceutical Ingredient (API) Sales: Taro synthesizes APIs internally and offers them through Taro API division for internal product use and external commercial supply.
Go-to-market motion1 record
Distribution channels4 records
Marketing channels3 records
Taro Pharmaceuticals product offering
Product offeringCore offering
Taro Pharmaceutical Industries develops, manufactures, and markets generic prescription and over-the-counter pharmaceutical products across dermatology, cardiology, pediatrics, and neurology therapeutic areas. The company operates a vertically integrated manufacturing model with in-house API synthesis and produces tablets, capsules, suspensions, solutions, creams, and ointments. Taro also markets a proprietary topical anesthetic (Pliaglis) and supplies APIs and finished dosage forms to the U.S., Canada, Israel, and international markets.
Product overview
Taro Pharmaceutical Industries is a research-based international pharmaceutical company that develops, manufactures, and markets generic prescription and over-the-counter medications. The company operates across four primary therapeutic areas: dermatology (topical corticosteroids, antifungals, and combination therapies), cardiology (cardiovascular drugs including Warfarin and Amiodarone), neurology (anticonvulsants including Carbamazepine and Phenytoin), and pediatrics (liquid formulations). Taro's product portfolio includes tablets, capsules, suspensions, solutions, creams, and ointments, with vertical integration through in-house Active Pharmaceutical Ingredient (API) synthesis. The company markets products under Taro label and private label in the U.S., Canada, Israel, and international markets. Since June 2024, Taro has been a privately held, wholly-owned subsidiary of Sun Pharmaceutical Industries following a $454 million merger.
Differentiator
Problem solved
Functional benefit
Brands
- Pliaglis: Topical local anaesthesia cream containing lidocaine and tetracaine for superficial dermatological procedures
Products and services
- Pliaglis (Lidocaine and Tetracaine 7%/7% Cream)
- Generic Prescription Products (Dermatology)
- Generic Prescription Products (Cardiology)
- Generic Prescription Products (Neurology)
- Generic Prescription Products (Pediatrics)
- Generic OTC Products (USA)
- Generic OTC Products (Canada)
- Active Pharmaceutical Ingredients (APIs)
- TaroPharma Branded Division Branded division established in 2003 in the U.S. for proprietary pharmaceutical products, providing a brand-name commercial vehicle alongside Taro's generic portfolio.
Quantifiable outcome
- Over $1 billion gross sales achieved (IMS Calendar Year 2012)
Companies that use Taro Pharmaceuticals
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles3 records
Taro Pharmaceuticals technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Taro Pharmaceuticals partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered minor.
- Rx OutreachminorTaro partners with the non-profit organization Rx Outreach to provide a Patient Assistance Program offering critically needed medications to eligible patients who cannot afford them.
- Antibe TherapeuticsminorSun Pharma subsidiary Taro planned to acquire 100% of Antibe Therapeutics, a biotechnology company in Ontario, Canada specializing in pain and inflammation management. The acquisition was expected to close before March 7, 2025 pending court approval. Antibe currently reports no revenue and is under court-appointed receivership.
- Strides Pharma Inc.minorStrides Pharma Inc., an India-based contract manufacturer, manufactures Taro's Children's Ibuprofen Oral Suspension products under a manufacturing agreement. Strides initiated a product recall in March 2026 following customer complaints about contamination.
Scale indicators4 records
Recent moves8 records
Expansion highlights5 records
Taro Pharmaceuticals competitors and assessment
Company assessmentDirect peers
- Perrigo Company: Perrigo is a US-based generic and OTC pharmaceutical company with a particularly strong dermatology/skin care portfolio. Directly comparable on generic Rx and OTC distribution through US retail pharmacy chains, private label programs, and topical formulation capabilities.
- Apotex Inc. Apotex is the largest Canadian generic pharmaceutical manufacturer, headquartered near Toronto. Directly comparable on Canadian manufacturing footprint, broad generic Rx/OTC portfolio, and emphasis on affordable access.
- Amneal Pharmaceuticals: Amneal is a US-focused generic and specialty pharmaceutical manufacturer with a broad portfolio spanning injectables, topicals and oral solids. Comparable on multi-therapeutic-area generic strategy and US retail/wholesale distribution.
- Lannett Company: Lannett is a US-focused generic pharmaceutical manufacturer with a broad solid-oral and topical portfolio. Comparable as a smaller-cap US generic competitor serving pharmacy chains and wholesalers.
Broad incumbents
- Teva Pharmaceutical Industries: Teva is the world's largest generic manufacturer and Israel's flagship pharma company. Comparable on generic Rx across dermatology, neurology, and cardiology; Taro has historically been a smaller Israeli peer with overlapping therapeutic-area focus.
- Aurobindo Pharma: Aurobindo is one of India's largest generic manufacturers with strong US presence. Comparable on generic Rx breadth, dermatology/topicals, neurology portfolio, and vertical API integration.
- Sandoz (Novartis): Sandoz is the global generic and biosimilar arm of Novartis, with extensive US, Canadian, and European operations. Comparable across the full generic Rx/OTC spectrum including dermatology, cardiology and neurology therapeutic categories.
- Viatris (formerly Mylan): Viatris is a leading global generic and specialty pharma formed via Mylan/Upjohn merger. Comparable as a broad-line generic player across dermatology, neurology, and cardiology with worldwide distribution.
Others
- Sun Pharmaceutical Industries: Sun Pharma is Taro's parent company and India's largest pharma company. While not a competitor (Taro is its subsidiary), Sun Pharma is thematically related as a vertically integrated generic manufacturer with comparable dermatology/specialty ambitions and is a key direct peer for portfolio and capability benchmarking.
Emerging players
- Endo International: Endo (including its Par Pharmaceuticals generics segment) has historically been a direct US generic competitor with strength in dermatology/topicals, injectables and controlled substances. Comparable on retail pharmacy-channel generics competition.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Taro Pharmaceuticals social profiles
Digital presenceTaro Pharmaceuticals compliance and trust
Trust signalCompliance5 records
Taro Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Taro Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles5 records
Taro Pharmaceuticals subsidiaries and ownership
Company hierarchySubsidiaries1 record
Taro Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Taro Pharmaceuticals M&A and investment
M&A and investmentM&A5 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Taro Pharmaceuticals
What does Taro Pharmaceuticals do?
Taro Pharmaceutical Industries develops, manufactures, and markets generic prescription and over-the-counter pharmaceutical products across dermatology, cardiology, pediatrics, and neurology therapeutic areas. The company operates a vertically integrated manufacturing model with in-house API synthesis and produces tablets, capsules, suspensions, solutions, creams, and ointments. Taro also markets a proprietary topical anesthetic (Pliaglis) and supplies APIs and finished dosage forms to the U.S., Canada, Israel, and international markets.
Is Taro Pharmaceuticals a public or private company?
Taro Pharmaceuticals is a private company. It is classified as corporate owned and is currently operating.
When was Taro Pharmaceuticals founded?
Taro Pharmaceuticals was founded in 1950. It employs 5,001 to 10,000 people.
Where is Taro Pharmaceuticals based?
Taro Pharmaceuticals is headquartered in Haifa, Israel, in the Middle East region.
How does Taro Pharmaceuticals make money?
Two revenue lines are on record. Generic Pharmaceutical Sales are the primary driver. The others are active Pharmaceutical Ingredient (API) Sales.
Who are Taro Pharmaceuticals's main competitors?
Direct peers on record are Perrigo Company, Apotex Inc., Amneal Pharmaceuticals and Lannett Company. Broad incumbents are Teva Pharmaceutical Industries, Aurobindo Pharma, Sandoz (Novartis) and Viatris (formerly Mylan). Sun Pharmaceutical Industries is listed as an others. Endo International is listed as an emerging player.
Does Taro Pharmaceuticals have an API?
No public API is recorded for Taro Pharmaceuticals.
What industry is Taro Pharmaceuticals in?
Taro Pharmaceuticals's product category is Generic Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAK, Dermatology & Aesthetics Pharmaceuticals, with a secondary code of HLAIACAL, Dermatology Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.